Table 3

Association between clinical factors and ln(anti-RBD IgG) at day 15 following a third BNT162b2 booster in patients with SLE and RA

Characteristics	Univariable analysis			Multivariable analysis
Characteristics	Regression coefficient	95% CI	P value	Regression coefficient	95% CI	P value
Age	0.02	−0.01 to 0.05	0.2	−0.01	−0.05 to 0.03	0.55
Sex
Male	Ref			Ref
Female	−0.18	−0.44 to 0.66	0.7	−0.12	−0.91 to 0.66	0.75
Diagnosis
SLE	Ref			Ref
RA	0.3	−0.16to 0.77	0.2	0.3	−0.22, to 0.83	0.25
Initial vaccine regimen
AZD1222/BNT162b2	Ref			Ref
AZD1222/AZD1222	0.02	−0.54 to 0.58	0.95	0.06	−0.62 to 0.75	0.85
Inactivated/inactivated	−0.71	−1.31 to –0.12	0.02	−0.85	−1.65 to –0.05	0.03
Interval between the second dose of initial vaccine and third BNT162b2 booster	0.002	−0.01 to 0.02	0.8	0.01	−0.01 to 0.03	0.27
Total immunosuppressive load	−0.41	−0.64 to –0.18	0.0007	−0.39	−0.63 to –0.14	0.002